文献速递消化系统肿瘤

初治不可切除结直肠癌肝转移患者的一线系统治疗策略(CAIRO5):荷兰结直肠癌组开放标签、多中心、随机、对照3期研究

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
PubMed 文献 · Lancet Oncol · 2023-06-14

CAIRO5研究纳入初治不可切除结直肠癌肝转移患者,按原发灶部位及RAS/BRAFV600E状态分组:右半或突变型随机接受FOLFOX/FOLFIRI+贝伐珠单抗(A组)或FOLFOXIRI+贝伐珠单抗(B组);左半且野生型随机接受FOLFOX/FOLFIRI+贝伐珠单抗(C组)或FOLFOX/FOLFIRI+帕尼单抗(D组)。B组较A组延长无进展生存期,D组较C组无临床获益且毒性增加。

要点

  • 右半或RAS/BRAFV600E突变患者中,FOLFOXIRI+贝伐珠单抗较FOLFOX/FOLFIRI+贝伐珠单抗延长中位无进展生存期。
  • 左半且RAS/BRAFV600E野生型患者中,帕尼单抗联合化疗较贝伐珠单抗联合化疗无临床获益且毒性增加。
  • FOLFOXIRI+贝伐珠单抗组严重不良事件及治疗相关死亡例数较多。

核心结论

  • 在初治不可切除结直肠癌肝转移患者中,右半或RAS/BRAFV600E突变原发肿瘤患者首选FOLFOXIRI-贝伐珠单抗治疗。
  • 左半且RAS/BRAFV600E野生型肿瘤患者中,在FOLFOX或FOLFIRI基础上加用帕尼单抗较贝伐珠单抗无临床获益,且与更多毒性相关。

研究设计与样本

  • 开放标签、多中心、随机、对照3期研究(CAIRO5),在46家荷兰和1家比利时二级和三级中心入组。
  • 纳入年龄18岁及以上、组织学确诊结直肠癌、已知RAS/BRAFV600E突变状态、WHO体能状态0-1、初治不可切除结直肠癌肝转移的患者。
  • 可切除性由肝脏外科和放射科专家小组依据预设标准在基线和此后每2个月集中评估。
  • 右半原发肿瘤或RAS或BRAFV600E突变患者1:1随机接受FOLFOX或FOLFIRI+贝伐珠单抗(A组)或FOLFOXIRI+贝伐珠单抗(B组);左半且RAS和BRAFV600E野生型患者1:1随机接受FOLFOX或FOLFIRI+贝伐珠单抗(C组)或FOLFOX或FOLFIRI+帕尼单抗(D组),每14天一次,最多12周期。
  • 2014年11月13日至2022年1月31日共随机分配530例患者(男性327例[62%],女性203例[38%];中位年龄62岁[IQR 54-69]):A组148例(28%)、B组146例(28%)、C组118例(22%)、D组118例(22%);C组和D组因无效提前关闭。

主要发现

  • 改良意向治疗人群共521例(A组147例、B组144例、C组114例、D组116例)。
  • A组和B组中位随访51.1个月(95% CI 47.7-53.1),C组和D组中位随访49.9个月(95% CI 44.5-52.5)。
  • 中位无进展生存期:A组9.0个月(95% CI 7.7-10.5)vs B组10.6个月(95% CI 9.9-12.1)(分层HR 0.76[95% CI 0.60-0.98];p=0.032);C组10.8个月(95% CI 9.9-12.6)vs D组10.4个月(95% CI 9.8-13.0)(分层HR 1.11[95% CI 0.84-1.48];p=0.46)。
  • A组和B组最常见的3-4级不良事件:中性粒细胞减少(A组19例[13%] vs B组57例[40%];p<0.0001)、高血压(A组21例[14%] vs B组20例[14%];p=1.00)、腹泻(A组5例[3%] vs B组28例[19%];p<0.0001)。
  • C组和D组最常见的3-4级不良事件:中性粒细胞减少(C组29例[25%] vs D组24例[21%];p=0.44)、皮肤毒性(C组1例[1%] vs D组29例[25%];p<0.0001)、高血压(C组20例[18%] vs D组8例[7%];p=0.016)、腹泻(C组5例[4%] vs D组18例[16%];p=0.0072)。

关键数值与推荐

  • 贝伐珠单抗静脉给药5 mg/kg;帕尼单抗静脉给药6 mg/kg。
  • FOLFIRI方案:伊立替康180 mg/m²静脉输注,亚叶酸钙400 mg/m²,随后氟尿嘧啶400 mg/m²静脉推注,随后氟尿嘧啶2400 mg/m²持续输注。
  • FOLFOX方案:奥沙利铂85 mg/m²静脉给药,联合与FOLFIRI相同的亚叶酸钙和氟尿嘧啶方案。
  • FOLFOXIRI方案:伊立替康165 mg/m²静脉给药,随后奥沙利铂85 mg/m²静脉输注联合亚叶酸钙400 mg/m²,随后氟尿嘧啶3200 mg/m²持续输注。

临床怎么用

  • 右半或RAS或BRAFV600E突变原发肿瘤的初治不可切除结直肠癌肝转移患者,首选FOLFOXIRI-贝伐珠单抗。
  • 左半且RAS和BRAFV600E野生型肿瘤患者,在FOLFOX或FOLFIRI基础上加用帕尼单抗较贝伐珠单抗无临床获益且毒性更多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with initially unresectable colorectal cancer liver metastases might qualify for local treatment with curative intent after reducing the tumour size by induction systemic treatment. We aimed to compare the currently most active induction regimens. METHODS: In this open-label, multicentre, randomised, phase 3 study (CAIRO5), patients aged 18 years or older with histologically confirmed colorectal cancer, known RAS/BRAFV600E mutation status, WHO performance status of 0-1, and initially unresectable colorectal cancer liver metastases were enrolled at 46 Dutch and one Belgian secondary and tertiary centres. Resectability or unresectability of colorectal cancer liver metastases was assessed centrally by an expert panel of liver surgeons and radiologists, at baseline and every 2 months thereafter by predefined criteria. Randomisation was done centrally with the minimisation technique via a masked web-based allocation procedure. Patients with right-sided primary tumour site or RAS or BRAFV600E mutated tumours were randomly assigned (1:1) to receive FOLFOX or FOLFIRI plus bevacizumab (group A) or FOLFOXIRI plus bevacizumab (group B). Patients with left-sided and RAS and BRAFV600E wild-type tumours were randomly assigned (1:1) to receive FOLFOX or FOLFIRI plus bevacizumab (group C) or FOLFOX or FOLFIRI plus panitumumab (group D), every 14 days for up to 12 cycles. Patients were stratified by resectability of colorectal cancer liver metastases, serum lactate dehydrogenase concentration, choice of irinotecan versus oxaliplatin, and BRAFV600E mutation status (for groups A and B). Bevacizumab was administered intravenously at 5 mg/kg. Panitumumab was administered intravenously at 6 mg/kg. FOLFIRI consisted of intravenous infusion of irinotecan at 180 mg/m2 with folinic acid at 400 mg/m2, followed by bolus fluorouracil at 400 mg/m2 intravenously, followed by continuous infusion of fluorouracil at 2400 mg/m2. FOLFOX consisted of oxaliplatin at 85 mg/m2 intravenously together with the same schedule of folinic acid and fluorouracil as in FOLFIRI. FOLFOXIRI consisted of irinotecan at 165 mg/m2 intravenously, followed by intravenous infusion of oxaliplatin at 85 mg/m2 with folinic acid at 400 mg/m2, followed by continuous infusion of fluorouracil at 3200 mg/m2. Patients and investigators were not masked to treatment allocation. The primary outcome was progression-free survival, analysed on a modified intention-to-treat basis, excluding patients who withdrew consent before starting study treatment or violated major entry criteria (no metastatic colorectal cancer, or previous liver surgery for colorectal cancer liver metastases). The study is registered with ClinicalTrials.gov, NCT02162563, and accrual is complete. FINDINGS: Between Nov 13, 2014, and Jan 31, 2022, 530 patients (327 [62%] male and 203 [38%] female; median age 62 years [IQR 54-69]) were randomly assigned: 148 (28%) patients to group A, 146 (28%) patients to group B, 118 (22%) patients to group C, and 118 (22%) patients to group D. Groups C and D were prematurely closed for futility. 521 patients were included in the modified intention-to-treat population (147 in group A, 144 in group B, 114 in group C, and 116 in group D). The median follow-up at the time of this analysis was 51·1 months (95% CI 47·7-53·1) in groups A and B and 49·9 months (44·5-52·5) in in groups C and D. Median progression-free survival was 9·0 months (95% CI 7·7-10·5) in group A versus 10·6 months (9·9-12·1) in group B (stratified hazard ratio [HR] 0·76 [95% CI 0·60-0·98]; p=0·032), and 10·8 months (95% CI 9·9-12·6) in group C versus 10·4 months (9·8-13·0) in group D (stratified HR 1·11 [95% CI 0·84-1·48]; p=0·46). The most frequent grade 3-4 events in groups A and B were neutropenia (19 [13%] patients in group A vs 57 [40%] in group B; p<0·0001), hypertension (21 [14%] vs 20 [14%]; p=1·00), and diarrhoea (five [3%] vs 28 [19%]; p<0·0001), and in groups C and D were neutropenia (29 [25%] vs 24 [21%]; p=0·44), skin toxicity (one [1%] vs 29 [25%]; p<0·0001), hypertension (20 [18%] vs eight [7%]; p=0·016), and diarrhoea (five [4%] vs 18 [16%]; p=0·0072). Serious adverse events occurred in 46 (31%) patients in group A, 75 (52%) patients in group B, 41 (36%) patients in group C, and 49 (42%) patients in group D. Seven treatment-related deaths were reported in group B (two due to multiorgan failure, and one each due to sepsis, pneumonia, portal vein thrombosis, septic shock and liver failure, and sudden death), one in group C (multiorgan failure), and three in group D (cardiac arrest, pulmonary embolism, and abdominal sepsis). INTERPRETATION: In patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI-bevacizumab was the preferred treatment in patients with a right-sided or RAS or BRAFV600E mutated primary tumour. In patients with a left-sided and RAS and BRAFV600E wild-type tumour, the addition of panitumumab to FOLFOX or FOLFIRI showed no clinical benefit over bevacizumab, but was associated with more toxicity. FUNDING: Roche and Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bond MJG, Bolhuis K, Loosveld OJL, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023. PMID: 37329889. doi:10.1016/S1470-2045(23)00219-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。